

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Application Number</i>	10/555,286
				<i>§ 371 Date</i>	October 17, 2006
				<i>First Named Inventor</i>	Juan M. JIMENEZ MAYORGA
				<i>Art Unit</i>	1626
				<i>Examiner Name</i>	Sun Jae Y. LOEWE
Sheet	1	of	1	<i>Attorney Docket Number</i>	09605.0016-00000

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	1	JP-A-2002-201168	07-16-2002	Kaken Pharm Co. Ltd.		

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
	2	L. DUCRY et al., "Synthesis of 1,2,5-Thiadiazolidin-3-one 1,1-Dioxide Derivatives and Evaluation of Their Affinity for MHC Class-II Proteins," Helvetica Chimica Acta, 82: 2432-2447 (1999).	
	3	English-language abstract of JP-A-2002-201168 (2002).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.